Soligenix Q3 2026 net loss narrows 56% to $1.1 million

By Public Technologies
  • Soligenix's third-quarter net loss narrowed 56% year over year to $1.1 million, with no revenue.
  • Research and development expenses fell 75% to $400,000 due to lower costs for the terminated FLASH2 trial and related HyBryte development.
  • Approximately $9 million in cash and cash equivalents at September 30, 2026, should fund operations into the second quarter of 2028.
  • Management is evaluating partnerships, licensing and potential mergers and acquisitions while advancing its rare-disease pipeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611060730PR_NEWS_USPR_____PH90361) on November 06, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk